BR112012032816A2 - composição farmacêutica de liberação controlada, e, métodos para reduzir o efeito alimentar de uma composição de liberação controlada, reduzir o período de tempo necessário para que seja alcançado um estado estável para a metformina, para aperfeiçoar a biodisponibilidade de uma forma de dosagem de liberação controlada de matriz - Google Patents
composição farmacêutica de liberação controlada, e, métodos para reduzir o efeito alimentar de uma composição de liberação controlada, reduzir o período de tempo necessário para que seja alcançado um estado estável para a metformina, para aperfeiçoar a biodisponibilidade de uma forma de dosagem de liberação controlada de matrizInfo
- Publication number
- BR112012032816A2 BR112012032816A2 BR112012032816A BR112012032816A BR112012032816A2 BR 112012032816 A2 BR112012032816 A2 BR 112012032816A2 BR 112012032816 A BR112012032816 A BR 112012032816A BR 112012032816 A BR112012032816 A BR 112012032816A BR 112012032816 A2 BR112012032816 A2 BR 112012032816A2
- Authority
- BR
- Brazil
- Prior art keywords
- controlled release
- reducing
- composition
- pharmaceutical composition
- metformin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
Abstract
composição farmacêutica de liberação controlada, e, métodos para reduzir o efeito alimentar de uma composição de liberação controlada, reduzir o período de tempo necessário para que seja alcançado um estado estável para a metformina, para aperfeiçoar a biodisponibilidade de uma forma de dosagem de liberação controlada de matriz. a presente invenção provê uma composição farmacêutica de liberação controlada, que exibe um efeito alimentar reduzido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35725110P | 2010-06-22 | 2010-06-22 | |
PCT/US2011/041218 WO2011163206A2 (en) | 2010-06-22 | 2011-06-21 | Controlled release compositions with reduced food effect |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012032816A2 true BR112012032816A2 (pt) | 2016-11-08 |
Family
ID=45328888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012032816A BR112012032816A2 (pt) | 2010-06-22 | 2011-06-21 | composição farmacêutica de liberação controlada, e, métodos para reduzir o efeito alimentar de uma composição de liberação controlada, reduzir o período de tempo necessário para que seja alcançado um estado estável para a metformina, para aperfeiçoar a biodisponibilidade de uma forma de dosagem de liberação controlada de matriz |
Country Status (13)
Country | Link |
---|---|
US (1) | US8486453B2 (pt) |
EP (1) | EP2585052A4 (pt) |
JP (1) | JP2013533241A (pt) |
KR (1) | KR20140007247A (pt) |
CN (1) | CN103037849A (pt) |
AR (1) | AR084698A1 (pt) |
AU (1) | AU2011271124A1 (pt) |
BR (1) | BR112012032816A2 (pt) |
CA (1) | CA2802335A1 (pt) |
MX (1) | MX2012015188A (pt) |
RU (1) | RU2012155890A (pt) |
TW (1) | TW201206503A (pt) |
WO (1) | WO2011163206A2 (pt) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
EP2540725A1 (de) | 2006-05-04 | 2013-01-02 | Boehringer Ingelheim International GmbH | Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
NZ594487A (en) | 2009-02-13 | 2013-11-29 | Boehringer Ingelheim Int | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
NZ599298A (en) | 2009-11-27 | 2014-11-28 | Boehringer Ingelheim Int | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
JP6034781B2 (ja) | 2010-05-05 | 2016-11-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 併用療法 |
EP3725325B1 (en) | 2010-06-24 | 2023-05-31 | Boehringer Ingelheim International GmbH | Diabetes therapy |
US20130251795A1 (en) * | 2010-07-30 | 2013-09-26 | Ranbaxy Laboratories Limited | Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
DK2731947T3 (en) | 2011-07-15 | 2019-04-23 | Boehringer Ingelheim Int | SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES |
LT3326611T (lt) * | 2012-02-22 | 2020-08-25 | Duchesnay Inc. | Doksilamino ir piridoksino ir (arba) jų metabolitų ar druskų vaisto forma |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
UY34856A (es) * | 2012-07-03 | 2013-12-31 | Bayer Pharma AG | Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida |
WO2014080383A1 (en) * | 2012-11-26 | 2014-05-30 | Ranbaxy Laboratories Limited | Pharmaceutical composition of dipeptidyl peptidase-iv (dpp-iv) inhibitors in combination with other antidiabetics |
JP6379194B2 (ja) | 2013-07-22 | 2018-08-22 | デュシネイ・インコーポレイテッド | 悪心及び嘔吐の管理のための組成物 |
US9452181B2 (en) | 2013-07-22 | 2016-09-27 | Duchesnay Inc. | Composition for the management of nausea and vomiting |
CN103655570B (zh) * | 2013-12-11 | 2016-07-06 | 深圳翰宇药业股份有限公司 | 西格列汀与二甲双胍复方缓释制剂及其制备方法 |
WO2015101916A1 (en) | 2013-12-30 | 2015-07-09 | Mylan Laboratories Ltd. | Process for the preparation of empagliflozin |
CN104739835A (zh) * | 2013-12-30 | 2015-07-01 | 中美华世通生物医药科技(武汉)有限公司 | 一种治疗糖尿病的新型药物组合物 |
WO2015130083A1 (ko) * | 2014-02-25 | 2015-09-03 | 동아에스티 주식회사 | 용법이 개선된 엔테카비어를 함유하는 약학적 조성물 |
KR101633292B1 (ko) * | 2014-02-25 | 2016-06-24 | 동아에스티 주식회사 | 용법이 개선된 엔테카비어를 함유하는 약학적 조성물 |
JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dpp−4阻害薬の医学的使用 |
CN105287581A (zh) * | 2014-07-15 | 2016-02-03 | 上海星泰医药科技有限公司 | 阿格列汀二甲双胍缓释片及其制备方法 |
TWI595874B (zh) | 2014-08-29 | 2017-08-21 | 達契斯奈股份有限公司 | 多西拉敏及吡哆醇及/或其代謝產物或鹽之多模式釋放調配物 |
RU2690372C2 (ru) * | 2015-04-20 | 2019-06-03 | Тви Биотекнолоджи, Инк. | Лекарственные средства, содержащие диацереин, и способы снижения уровней мочевой кислоты в крови с его использованием |
TWI684465B (zh) * | 2015-04-22 | 2020-02-11 | 安成生物科技股份有限公司 | 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法 |
CN105055413A (zh) * | 2015-07-23 | 2015-11-18 | 上海市第六人民医院 | 一种小檗碱和瑞格列奈的药物组合物 |
CN105496970A (zh) * | 2015-12-18 | 2016-04-20 | 北京华禧联合科技发展有限公司 | 含有利格列汀的组合物及其制备方法 |
CN106924208A (zh) * | 2015-12-30 | 2017-07-07 | 深圳翰宇药业股份有限公司 | 一种复方达格列净二甲双胍缓释片及其制备方法 |
WO2017153939A1 (en) * | 2016-03-10 | 2017-09-14 | Aurobindo Pharma Limited | Pharmaceutical composition comprising canagliflozin, process of preparation and use thereof |
CA3022202A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
CN112074287A (zh) | 2018-04-06 | 2020-12-11 | 阿玛治疗公司 | 用于控释治疗剂的组合物 |
IT201800011119A1 (it) | 2018-12-14 | 2020-06-14 | Dpl Pharma S P A | Composizioni farmaceutiche orali solide per la somministrazione cronotropica di sitagliptin |
TR201916829A2 (tr) * | 2019-10-31 | 2021-05-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dapagli̇flozi̇n ve metformi̇n i̇çeren çi̇ft katmanli tablet formülasyonlari |
CN110974792A (zh) * | 2019-12-26 | 2020-04-10 | 南京亿华药业有限公司 | 一种结晶性药物片剂及其制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
US6360257B1 (en) * | 1998-01-30 | 2002-03-19 | Telefonaktiebolaget L M Ericsson (Publ) | Managing group IP addresses in mobile end stations |
US6099859A (en) * | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
US20030187074A1 (en) * | 2002-03-04 | 2003-10-02 | Javed Hussain | Oral compositions for treatment of diabetes |
AU2003261298A1 (en) * | 2002-08-02 | 2004-02-23 | Penwest Pharmaceuticals Company | Sustained release formulations of metformin |
KR101363679B1 (ko) * | 2002-09-20 | 2014-02-14 | 안드렉스 랩스 엘엘씨 | 약제학적 정제 |
US7785627B2 (en) * | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
ES2340997T3 (es) * | 2003-07-24 | 2010-06-14 | Wockhardt Limited | Composiciones orales para el tratamiento de diabetes. |
CN1968680A (zh) * | 2003-10-31 | 2007-05-23 | 阿尔扎公司 | 促进加巴喷丁和普加巴林的吸收的组合物和剂型 |
RU2006118801A (ru) * | 2003-10-31 | 2007-12-10 | Алза Корпорейшн (Us) | Композиции и лекарственные формы для усиления всасывания габапентина и прегабалина |
WO2010045656A2 (en) * | 2008-10-17 | 2010-04-22 | Nectid, Inc. | Novel sglt2 inhibitor dosage forms |
-
2011
- 2011-06-21 BR BR112012032816A patent/BR112012032816A2/pt not_active IP Right Cessation
- 2011-06-21 CA CA2802335A patent/CA2802335A1/en not_active Abandoned
- 2011-06-21 CN CN201180031366XA patent/CN103037849A/zh active Pending
- 2011-06-21 EP EP11798742.0A patent/EP2585052A4/en not_active Withdrawn
- 2011-06-21 JP JP2013516682A patent/JP2013533241A/ja active Pending
- 2011-06-21 US US13/164,995 patent/US8486453B2/en not_active Expired - Fee Related
- 2011-06-21 AU AU2011271124A patent/AU2011271124A1/en not_active Abandoned
- 2011-06-21 MX MX2012015188A patent/MX2012015188A/es active IP Right Grant
- 2011-06-21 WO PCT/US2011/041218 patent/WO2011163206A2/en active Application Filing
- 2011-06-21 RU RU2012155890/15A patent/RU2012155890A/ru not_active Application Discontinuation
- 2011-06-21 AR ARP110102144A patent/AR084698A1/es unknown
- 2011-06-21 KR KR1020127033481A patent/KR20140007247A/ko not_active Application Discontinuation
- 2011-06-22 TW TW100121863A patent/TW201206503A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2013533241A (ja) | 2013-08-22 |
RU2012155890A (ru) | 2014-07-27 |
EP2585052A2 (en) | 2013-05-01 |
CA2802335A1 (en) | 2011-12-29 |
CN103037849A (zh) | 2013-04-10 |
US20110311594A1 (en) | 2011-12-22 |
MX2012015188A (es) | 2013-05-20 |
AU2011271124A1 (en) | 2013-01-10 |
WO2011163206A2 (en) | 2011-12-29 |
KR20140007247A (ko) | 2014-01-17 |
WO2011163206A4 (en) | 2012-04-26 |
EP2585052A4 (en) | 2014-10-01 |
AR084698A1 (es) | 2013-06-05 |
US8486453B2 (en) | 2013-07-16 |
TW201206503A (en) | 2012-02-16 |
WO2011163206A3 (en) | 2012-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012032816A2 (pt) | composição farmacêutica de liberação controlada, e, métodos para reduzir o efeito alimentar de uma composição de liberação controlada, reduzir o período de tempo necessário para que seja alcançado um estado estável para a metformina, para aperfeiçoar a biodisponibilidade de uma forma de dosagem de liberação controlada de matriz | |
CL2014002077A1 (es) | Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple. | |
CL2015000177A1 (es) | Composición para el tratamiento de la hiperlipidemia que comprende un derivado de oxintomodulina | |
BR112013006769A2 (pt) | combinação sinérgica de um anticorpo específico para cd38 | |
ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
CU20140025A7 (es) | Pirimidinas anilladas sustituidas | |
ECSP13012668A (es) | Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso | |
BR112014009391A2 (pt) | dosagem faseada de clopidogrel | |
BR112013031794A2 (pt) | novos derivados de oxintomodulina e composição farmacêutica para o tratamento da obesidade compreendendo os mesmos | |
CR20140036A (es) | Compuesto inhibidor de la señalización de la trayectoria notch | |
UY33246A (es) | Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas | |
CU20110153A7 (es) | Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido | |
BR112012020989A2 (pt) | composições veterinárias | |
BR112015011430A2 (pt) | composição para liberação imediata e prolongada | |
CL2015000289A1 (es) | Compuesto citostatico derivado de niclosamida y compuesto alquilante derivado de 2,3,4,6,8-pentazabiciclo[4.3.0]nona-2,7-trieno; composicion farmaceutica que los comprende; y metodo para determinar si el tratamiento para un paciente con un tumor solido es adecuado. | |
CR20120008A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
IL229166A0 (en) | A coating composition suitable for dosage forms of drugs or food supplements | |
PL2720681T3 (pl) | Kompozycja powlekająca odpowiednia do farmaceutycznych lub nutraceutycznych postaci dawkowania | |
BR112013019522A2 (pt) | dissialil lacto-n-tetraose (dslnt) ou as variantes, os isômeros, os análogos e os derivados da mesma para prevenir ou inibir doença do intestino | |
BR112014009889A2 (pt) | compostos dissubstituídos, compostos e composição farmacêutica | |
BR112013022147A2 (pt) | composto, composição farmacêutica, método de inibição da pask, método de tratamento de uma doença, método para alcançar um efeito em um paciente e método de tratamento de uma doença mediada pela pask | |
CU24163B1 (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib | |
UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias | |
BR112013016590A2 (pt) | uso de estabilizantes de glutamina | |
AR082215A1 (es) | Composicion farmaceutica agradable al paladar |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |